US9119862B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9119862-B2 |
| Application number | US-201414335020-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 18, 2014 |
| Priority date | Jun 29, 2011 |
| Publication date | Sep 1, 2015 |
| Grant date | Sep 1, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ 12 -prostaglandin J 3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. Δ 12 -prostaglandin J 3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. Δ 12 -prostaglandin J 3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.
Opening claim text (preview).
What is claimed is: 1. A composition comprising a pharmaceutically acceptable carrier and an isolated or synthesized Δ 12 -prostaglandin J 3 (Δ 12 PGJ 3 ), for inducing p53 expression in a cancer stem cell. 2. The composition of claim 1 , further comprising a second anti-cancer drug. 3. The composition of claim 2 , wherein the second anti-cancer drug is imatinib. 4. A method for inducing P53 expression in cancer stem ce…
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.